MRD status during maintenance therapy, according to patients’ baseline characteristics, and treatment response at the start and after 12 months of maintenance therapy
| . | MRD status . | P . | |
|---|---|---|---|
| Negative, N = 127 . | Positive, N = 382 . | ||
| Age, no. (%), y | .14 | ||
| <60 y | 62 (22.4) | 215 (77.6) | |
| ≥60 y | 65 (28.0) | 167 (72.0) | |
| Sex, no. (%) | .19 | ||
| Male | 68 (22.8) | 230 (77.2) | |
| Female | 59 (28.0) | 152 (72.0) | |
| ISS disease stage, no. (%) | .61 | ||
| Stage I | 38 (23.0) | 127 (77.0) | |
| Stage II | 67 (26.9) | 182 (73.1) | |
| Stage III | 22 (23.2) | 73 (76.8) | |
| Cytogenetic risk profile, no. (%) | .40* | ||
| Standard risk | 85 (26.2) | 239 (73.8) | |
| High risk | 23 (31.1) | 51 (68.9) | |
| FISH failure | 19 (17.1) | 92 (82.9) | |
| Treatment arm, no. (%) | .01 | ||
| RVD-alone | 54 (20.5) | 210 (79.5) | |
| Transplantation | 73 (29.8) | 172 (70.2) | |
| Response at the beginning of maintenance therapy, no. (%)† | .006‡ | ||
| Complete response stringent or not | 54 (49.5) | 55 (50.5) | |
| VGPR | 36 (31.3) | 79 (68.7) | |
| Partial response | 0 (0.0) | 134 (100.0) | |
| Stable disease | 0 (0.0) | 8 (100.0) | |
| Response after 12 mo of maintenance therapy, no. (%)† | <.001‡ | ||
| Complete response stringent or not | 83 (59.7) | 56 (40.3) | |
| VGPR | 9 (20.5) | 35 (79.5) | |
| Partial response | 0 (0.0) | 56 (100.0) | |
| . | MRD status . | P . | |
|---|---|---|---|
| Negative, N = 127 . | Positive, N = 382 . | ||
| Age, no. (%), y | .14 | ||
| <60 y | 62 (22.4) | 215 (77.6) | |
| ≥60 y | 65 (28.0) | 167 (72.0) | |
| Sex, no. (%) | .19 | ||
| Male | 68 (22.8) | 230 (77.2) | |
| Female | 59 (28.0) | 152 (72.0) | |
| ISS disease stage, no. (%) | .61 | ||
| Stage I | 38 (23.0) | 127 (77.0) | |
| Stage II | 67 (26.9) | 182 (73.1) | |
| Stage III | 22 (23.2) | 73 (76.8) | |
| Cytogenetic risk profile, no. (%) | .40* | ||
| Standard risk | 85 (26.2) | 239 (73.8) | |
| High risk | 23 (31.1) | 51 (68.9) | |
| FISH failure | 19 (17.1) | 92 (82.9) | |
| Treatment arm, no. (%) | .01 | ||
| RVD-alone | 54 (20.5) | 210 (79.5) | |
| Transplantation | 73 (29.8) | 172 (70.2) | |
| Response at the beginning of maintenance therapy, no. (%)† | .006‡ | ||
| Complete response stringent or not | 54 (49.5) | 55 (50.5) | |
| VGPR | 36 (31.3) | 79 (68.7) | |
| Partial response | 0 (0.0) | 134 (100.0) | |
| Stable disease | 0 (0.0) | 8 (100.0) | |
| Response after 12 mo of maintenance therapy, no. (%)† | <.001‡ | ||
| Complete response stringent or not | 83 (59.7) | 56 (40.3) | |
| VGPR | 9 (20.5) | 35 (79.5) | |
| Partial response | 0 (0.0) | 56 (100.0) | |
FISH, fluorescence in situ hybridization.
The FISH failure category was excluded.
Among the 127 patients who were MRD− during maintenance therapy, 90 achieved negativity at the beginning of maintenance therapy, and 92 after completion of maintenance therapy.
Patients who achieved less than a VGPR were excluded.